Advertisement

Erdafitinib for FGFR-Altered Advanced Urothelial Carcinoma


This week, we review a phase II trial of erdafitinib in urothelial carcinoma with an FGFR alteration. We also talk about a report from the World Health Organization on tobacco use worldwide. Then, we discuss two recent U.S. Food and Drug Administration approvals in prostate cancer and a rare joint tumor.




Advertisement
Advertisement

Advertisement



;
Advertisement